We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Have you been eager to see how Synchrony Financial (SYF - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this popular global professional services company’s earnings release this morning.
An Earnings Beat
Synchrony Financial came out with adjusted earnings of 92 cents per share, which beat the Zacks Consensus Estimate of 82 cents.
Synchrony Financial has a decent earnings surprise history. The company delivered positive surprises in each of the last four quarters, with an average beat of 9.46%.
Key Q2 Statistics
Net interest income increased 3% year over year to $3.7 billion.
Provision for loan losses decreased 3% to $1.3 billion over the prior year quarter.
Net interest margin decreased 72 basis points to 15.33%.
Return on assets was 2.9% and return on equity was 19.4%.
Efficiency ratio was 31.0%, up 10 basis points year over year.
What Zacks Rank Says
Synchrony Financial carries a Zacks Rank #3 (Hold). However, since the latest earnings performance yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this Synchrony Financial earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Synchrony Financial's (SYF) Q2 Earnings Surpass Estimates
Have you been eager to see how Synchrony Financial (SYF - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this popular global professional services company’s earnings release this morning.
An Earnings Beat
Synchrony Financial came out with adjusted earnings of 92 cents per share, which beat the Zacks Consensus Estimate of 82 cents.
Synchrony Financial Price and EPS Surprise
Synchrony Financial Price and EPS Surprise | Synchrony Financial Quote
Earnings Surprise History
Synchrony Financial has a decent earnings surprise history. The company delivered positive surprises in each of the last four quarters, with an average beat of 9.46%.
Key Q2 Statistics
Net interest income increased 3% year over year to $3.7 billion.
Provision for loan losses decreased 3% to $1.3 billion over the prior year quarter.
Net interest margin decreased 72 basis points to 15.33%.
Return on assets was 2.9% and return on equity was 19.4%.
Efficiency ratio was 31.0%, up 10 basis points year over year.
What Zacks Rank Says
Synchrony Financial carries a Zacks Rank #3 (Hold). However, since the latest earnings performance yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this Synchrony Financial earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>